In Brief: Biopool
This article was originally published in The Gray Sheet
Biopool: Receives 510(k) clearance to market its Chromolize kit for measuring the level of tissue plasminogen activator (tPA) in blood. The kit includes Biopool's Stabilyte blood collection tubes, used to stabilize tPA during blood collection for accurate tPA measurements. Measurement of tPA, which correlates with fibrinolytic (blood clot formation) potential, aids in evaluating thrombotic tendencies such as myocardial infarction, pulmonary embolism, deep-vein thrombosis and unstable angina...
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.